U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07625306) titled 'Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL' on May 27.
Brief Summary: CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in participants with elevated Lp(a) and recent acute coronary syndrome (ACS).
Study Start Date: Aug. 31
Study Type: INTERVENTIONAL
Condition:
Acute Coronary Syndrome (ACS)
Intervention:
DRUG: Pelacarsen
Pelacarsen 80 mg subcutaneously (s.c.) once a ...